A 5.4-point separation from placebo on the Hamilton Anxiety Rating Scale is not a rounding error. That is the signal Definium Therapeutics reported August 12 from its Phase 3 Voyage study of DT120 ODT in generalized anxiety disorder, with treated patients averaging an 11.6-point HAM-A improvement at week 12 versus 6.2 points in the placebo arm. For a program built around a single oral LSD dose administered without mandatory psychotherapy, that gap carries real weight.

The result lands on a foundation that was already more credible than most psychedelic-adjacent programs. Phase 2b data published in JAMA established a statistically significant dose-response relationship, and the 100 µg dose that Voyage tested was selected deliberately from that earlier work. What Voyage now adds is Phase 3 confirmation at a scale and design rigor the FDA will scrutinize in full. The HAM-A as primary endpoint is a conservative, well-validated choice for anxiety trials, which matters when the molecule is a scheduled substance and regulators have limited precedent for this class.

Definium entered this readout from a position of unusual financial stability for a clinical-stage company. Approximately $1.1 billion in cash and investments as of June 30, 2026, including nearly $758 million raised in a recent public offering, means the company does not need this readout to survive. It needs it to advance. That distinction changes how the data gets interpreted internally: this is not a lifeline, it is evidence for a regulatory conversation. GAD treatment remains heavily reliant on SSRIs and SNRIs approved years ago for depression, and DT120’s mechanism sits entirely outside that pharmacological lineage, which is both its competitive argument and its regulatory complication.

Voyage is the first of Definium’s two pivotal Phase 3 studies in generalized anxiety disorder to report. The second, Panorama, which adds a low-dose 50 µg arm, is expected to deliver topline results in September 2026. Separately, DT120 posted positive Phase 3 results in major depressive disorder, the Emerge study, in June 2026. The number to track now is whether the 5.4-point HAM-A difference holds or widens in that second study, because the FDA will treat the two trials as a package, not as isolated wins.

Source link: https://www.sec.gov/Archives/edgar/data/1813814/000110465926094528/tm2622948d1_8k.htm

+ posts

Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.